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The transcriptional coactivator PPAR gamma coactivator 1  (PGC-1) is a key regulator of metabolic
processes such as mitochondrial biogenesis and respiration in muscle and gluconeogenesis in liver. Reduced
levels of PGC-1 in humans have been associated with type II diabetes. PGC-1 contains a negative
regulatory domain that attenuates its transcriptional activity. This negative regulation is removed by
phosphorylation of PGC-1 by p38 MAPK, an important kinase downstream of cytokine signaling in muscle
and -adrenergic signaling in brown fat. We describe here the identification of p160 myb binding protein
(p160MBP) as a repressor of PGC-1. The binding and repression of PGC-1 by p160MBP is disrupted by p38
MAPK phosphorylation of PGC-1. Adenoviral expression of p160MBP in myoblasts strongly reduces PGC-1’s
ability to stimulate mitochondrial respiration and the expression of the genes of the electron transport system.
This repression does not require removal of PGC-1 from chromatin, suggesting that p160MBP is or recruits a
direct transcriptional suppressor. Overall, these data indicate that p160MBP is a powerful negative regulator of
PGC-1 function and provide a molecular mechanism for the activation of PGC-1 by p38 MAPK. The
discovery of p160MBP as a PGC-1 regulator has important implications for the understanding of energy
balance and diabetes.
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Most biological programs involving alterations in gene
expression are regulated by changes in amounts or ac-
tivities of DNA-binding transcription factors. However,
recent evidence has shown that transcriptional coactiva-
tors can be important targets for physiologic regulation.
PPAR gamma coactivator 1  (PGC-1) has emerged as a
key regulator of several aspects of mammalian energy
metabolism. It was originally cloned as a binding partner
for PPAR (Puigserver et al. 1998), but interacts with and
coactivates many transcription factors, such as nuclear
respiratory factor 1 (NRF-1), myocyte-enhancing factor-
2C (MEF2C), and most members of the nuclear hormone
receptor family (for review, see Puigserver and Spiegel-
man 2003).
PGC-1 activates a broad program of adaptive thermo-
genesis characteristic of brown fat cells when expressed
in white fat cells (Puigserver et al. 1998; Tiraby et al.
2003). This is characterized by mitochondrial biogenesis
and an induction of the uncoupling protein 1, resulting
in elevated respiration. PGC-1 expression in muscle
cells leads to elevated respiration and oxidative phos-
phorylation with increases in the expression of mito-
chondrial genes and the glucose transporter GLUT4 (Wu
et al. 1999; Michael et al. 2001; St-Pierre et al. 2003).
Importantly, expression of PGC-1 in skeletal muscle in
vivo via a transgene triggers the conversion of type IIb
muscle fibers to type IIa and type I fibers, as evidenced by
mitochondrial biogenesis and expression of myofibrillar
proteins characteristic of slow-twitch muscle (Lin et al.
2002; Handschin et al. 2003). Most recently, decreases in
skeletal muscle PGC-1 have been associated with hu-
man type 2 diabetes and those at risk for the develop-
ment of diabetes (Mootha et al. 2003; Patti et al. 2003).
PGC-1 is also associated with increased oxidative ca-
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pacity in heart. It is dramatically induced at birth when
the heart has an increased requirement for mitochon-
drial respiration (Lehman et al. 2000). Moreover, PGC-1
stimulates fatty acid oxidation in heart, which provides
fuel for the respiratory chain (Vega et al. 2000).
PGC-1 is induced in liver in response to fasting, and
activates key genes of the fasting response, including the
genes of the gluconeogenic pathway and -oxidation of
fatty acids (Herzig et al. 2001; Yoon et al. 2001; Puig-
server et al. 2003; Rhee et al. 2003). This is of critical
importance in diabetes because dysregulated gluconeo-
genesis is a key component of the hyperglycemia char-
acteristic of both type I and type II diabetes.
In addition to these physiological changes in PGC-1
gene expression, this coactivator is also controlled at the
posttranslational level. PGC-1 contains a negative
regulatory region between amino acids 170 and 350,
which reduces the function of the transcriptional activa-
tion domain located between amino acids 1 and 170
(Puigserver et al. 1999). This transcriptional suppression
can be relieved via phosphorylation by p38 MAPK at
residues Thr 262, Ser 265, and Thr 298 of murine PGC-
1, all within the negative regulatory domain. These
sites are likely to be physiologically relevant, as signal-
ing upstream of p38 MAPK is activated during certain
states of increased respiration and metabolic rates. For
example, p38 MAPK is activated downstream of inflam-
matory cytokine stimulation in muscle (Knutti et al.
2001; Puigserver et al. 2001) and 3-adrenergic stimula-
tion in brown adipocytes (Cao et al. 2001), correlating
with states of cachexia and cold exposure, respectively.
PGC-1 that has been phosphorylated by p38 MAPK is
both more stable and has augmented transcriptional ac-
tivity relative to unphosphorylated protein (Puigserver et
al. 2001). The increased stability of the p38 MAPK phos-
phorylated protein does not, however, fully explain the
observed increase in transcriptional coactivation. A mu-
tant PGC-1 with alanine substitutions at the phos-
phorylation sites has similarly increased stability, but is
much less active in stimulating mitochondrial gene ex-
pression and oxygen consumption (Puigserver et al.
2001). Hence, the p38 MAPK-mediated phosphorylation
is able to activate PGC-1 function through at least two
distinct mechanisms.
We describe here the identification of p160 myb bind-
ing protein (Mybbp1a, herein called p160MBP) as a repres-
sor of PGC-1 that interacts with PGC-1’s negative
regulatory domain and reduces its transcriptional and
biological activities. Moreover, p160MBP binding is dis-
rupted by p38 MAPK phosphorylation of PGC-1, pro-
viding a mechanistic explanation for the positive regu-
lation of this coactivator by p38 MAPK.
Results
p160MBP interacts with the regulatory domain
of PGC-1 and inhibits its transcriptional activity
To investigate the mechanism of regulation of PGC-1
through its suppressor domain, we performed affinity
chromatography using a GST-fusion protein containing
amino acids 200–400 of PGC-1 and nuclear extracts
from C2C12 myoblasts. The parent GST protein and
GST fused to amino acids 1–200 of PGC-1 [GST-
PGC1(1–200)] were used as controls. After binding and
washing, the GST proteins and associated proteins were
eluted with free glutathione, separated by SDS-PAGE,
and silver stained. A unique constellation of proteins
interacted with GST-PGC1(200–400) compared with
GST-PGC1(1–200) or the control GST protein (Fig. 1A).
Proteins binding to GST-PGC1(200–400) were excised
from SDS-PAGE gels and identified by a combination of
peptide mass fingerprinting using matrix-assisted laser
desorption/ionization-time-of-flight (MALDI-TOF) mass
spectrometry (MS), and mass spectrometric sequencing
using NanoES triple-quadruple MS/MS (Winkler et al.
2002). Several proteins containing hnRNP or splicing
motifs were among those found to interact with GST-
PGC1(200–400), highlighting PGC-1’s role in RNA pro-
cessing (Supplemental Table 1). We also purified two
components of the anaphase-promoting complex, tsg24
and cdc16. cdc16 is indicated in Figure 1A and will be ex-
amined in later experiments. Our attention is focused on
another interacting protein, p160MBP, because it was pre-
viously identified as a negative regulator of a transcription
factor, c-myb (Tavner et al. 1998). To confirm this identi-
fication, we used antibodies against p160MBP in Western
blots of the proteins purified with the GST fusions. As
shown in Figure 1B, p160MBP indeed interacts strongly
with GST-PGC1(200–400) compared with GST alone.
p160MBP has been previously shown to be expressed
ubiquitously and is posttranslationally processed in
some cells to create an N-terminal fragment of 67 kD,
p67MBP (Tavner et al. 1998). Previous work showed that
p160MBP did not alter c-myb’s transcriptional activity in
transfection assays, whereas p67MBP reduced c-myb tran-
scription by 80%.We clonedmouse p160MBP and p67MBP
separately into mammalian expression vectors and
tested them on PGC-1.
HIB1B brown fat cells were cotransfected with a fusion
protein connecting the yeast Gal4 DNA binding domain
(Gal4-DBD) with full-length PGC-1, along with an ap-
propriate Gal4-UAS-luciferase reporter, and p160MBP or
p67MBP. Luciferase assays were conducted 24 h later and
revealed that both p160MBP and p67MBP dramatically re-
pressed Gal4-PGC1 transcriptional activity, by 80%
and 96%, respectively (Fig. 1C). In contrast, a version of
PGC-1 that has lost its negative regulatory region,
Gal4-PGC1(170–350), was not significantly affected by
either p160MBP or p67MBP expression. These data dem-
onstrate that both p160MBP and p67MBP have inhibitory
effects on PGC-1 activity and that these effects are de-
pendent on the regulatory region of PGC-1 to which
these factors bind.
Wild-type PGC-1 does not bind to DNA directly, but
rather functions as a coactivator of transcription factors.
To study the effects of p160MBP and p67MBP on PGC-1
in a more native context, we cotransfected vectors ex-
pressing these proteins with PGC-1 and one of its tran-
scription factor targets, PPAR. A multimerized PPAR
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response element (DR-1) linked to a luciferase reporter
gene was used to measure transcriptional activity. Al-
though p160MBP and p67MBP had minimal effects on
PPAR alone, they both significantly diminished PGC-
1’s coactivation of PPAR (Fig. 1D). These results indi-
cate that both p160MBP and p67MBP are able to repress
PGC-1’s trancriptional coactivation in transient trans-
fection.
Both N- and C-terminal domains of p160MBP interact
with PGC-1
A series of deletions of p160MBP were constructed to de-
termine which regions of this protein are responsible for
the interaction with PGC-1. Given the repressive ef-
fects of p67MBP on PGC-1, it was expected that the N
terminus of this molecule would interact with PGC-1.
Therefore, in addition to the p67MBP protein, this N-ter-
minal region was also divided into three portions, amino
acids 1–200, 200–400, and 400–580. An expression vector
for the remainder of p160MBP, which is not encompassed
in p67MBP, was also generated and is termed p160C (Fig.
2A).
When in vitro translated portions of p160MBP were in-
cubated with GST-PGC1(200–400), it was clear that
PGC-1 interacted with p160MBP through both the N-
terminal and C-terminal halves of p160MBP (Fig. 2B).
Within the subdomains of the N terminus of p160MBP,
the only segment that showed detectable binding to
PGC-1was p160(200–400) (Fig. 2B). It is interesting that
p160MBP is predicted to contain two leucine zipper mo-
tifs, one at aa 307 to 335, and another at 900 to 928
(Tavner et al. 1998). Both of these lie within segments
that bind to PGC-1, and it is possible that they play
a role in this interaction. In fact, p160MBP interacts
with leucine-rich regions of c-myb and c-jun, and muta-
tions of specific leucines on PGC-1 disrupt p160MBP
binding (discussed in Fig. 3). Neither p160C nor any of
Figure 1. p160MBP interacts with GST-PGC1(200–400) and suppresses PGC-1-mediated transcription. C2C12 muscle cell nuclear
extracts were incubated with bacterially expressed GST fusion proteins on glutathione sepharose beads. PGC(1–200) is GST-PGC1(1–
200) and PGC(200–400) is GST-PGC1(200–400). The interacting proteins were run on an SDS-PAGE gel and (A) silver stained or (B)
Western blotted with antibodies against p160MBP. (C) p160MBP or p67MBP was cotransfected with Gal4-PGC1 or Gal4-PGC1(170–
350) and a UAS-luciferase reporter in HIB1B cells. Luciferase activity was measured after 24 h. (Asterisks) P < 0.001, paired t-test. (D)
PPAR and RXR with or without PGC-1 were cotransfected with a DR-1-luciferase reporter into HIB1B cells. p160MBP or p67MBP
were also added and luciferase levels were measured after 24 h. All luciferase assays were normalized for transfection efficiencies using
-galactosidase. (Asterisks) P < 0.001, paired t-test.
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the smaller fragments of p67MBP were able to suppress
the transcriptional activity of Gal4-PGC1 (data not
shown), suggesting that some of the key functional do-
mains of p160MBP lie outside of the PGC-1 interaction
region.
p38 MAPK phosphorylation of PGC-1 blocks
its interaction with p160MBP
p38 MAPK directly phosphorylates amino acids Thr 262,
Ser 265, and Thr 298 in the repressor region of PGC-1
and leads to a protein that is both more stable and more
transcriptionally active (Knutti et al. 2001; Puigserver et
al. 2001). The p38 MAPK sites are highly conserved
across species and are downstream of both cytokine and
-adrenergic signaling cascades (Tracey et al. 1987; Cao
et al. 2001). We therefore investigated the possibility
that phosphorylation of PGC-1 could interfere with
p160MBP binding to the negative regulatory region of
PGC-1. p38 MAPK was used to phosphorylate GST-
PGC1(200–400) in vitro under conditions in which the
vast majority of the protein becomes phosphorylated and
has reduced mobility in SDS-PAGE [GST-PGC(200–400)-
P] (Fig. 3A). Identical protein that was incubated with
p38 MAPK in the absence of ATP was used as a control
[GST-PGC1(200–400)]. As seen in Figure 3A, GST-PGC1
(200–400)-P bound much less p160MBP from C2C12 nu-
clear extracts than the mock phosphorylated GST-PGC1
(200–400) protein (Fig. 3A). In contrast, cdc16 binds
equally well to PGC-1 with or without phosphoryla-
tion. These data indicate that p38 MAPK phosphoryla-
tion of PGC-1 specifically inhibits its binding to p160MBP.
We also asked whether phosphorylation of PGC-1
disrupts its interaction with p160MBP in cells. Flag-
tagged PGC-1 (f:PGC1) and myc-tagged p160MBP were
cotransfected into BOSC cells and treated with the cy-
tokines interleukin-1 (IL-1), interleukin-1 (IL-1),
and tumor necrosis factor  (TNF) to induce p38
MAPK-mediated phosphorylation of PGC-1 (Puigserver
et al. 2001). PGC-1 was then immunoprecipitated and
the complex was run on SDS-PAGE and analyzed by
Western blotting. Despite the fact that cytokines in-
creased the amount of PGC-1 protein, as expected, less
myc-tagged p160MBP was immunoprecipitated with
PGC-1when cells were treated with cytokines (Fig. 3B).
We next examined the effects of p38 MAPK on PGC-
1 and p160MBP by measuring transcriptional activity in
cells. MKK6, the upstream activator of p38 MAPK, was
used to stimulate phosphorylation of Gal4-PGC1 in
C2C12 myoblasts. As shown previously (Knutti et al.
2001; Puigserver et al. 2001) and in Figure 3C, MKK6
activates the transcriptional activity of Gal4-PGC1.
However, whereas p160MBP and p67MBP suppress the
transcriptional activity of Gal4-PGC1, MKK6 com-
pletely relieves this suppression.
To confirm that the p38 MAPK modulation of the
PGC-1 and p160MBP interaction is a consequence of the
direct action of p38 MAPK on PGC-1, we created a
mutant of PGC-1 that replaces the phosphorylated resi-
dues with aspartic acids (PGC1-3D). The aspartate resi-
dues are used to mimic a phosphorylated version of
PGC-1. There may also be additional effects of MKK6
on other components of the PGC-1 pathway, but the
PGC1-3D mutant allows us to test the portion of the
MKK6 activation that directly targets PGC-1 protein
itself. As shown in Figure 3D, the mutated Flag-tagged
PGC-1 (f:PGC1-3D) coimmunoprecipitated signifi-
cantly less myc-tagged p160MBP when cotransfected in
BOSC cells. This mutant is more transcriptionally active
than wild-type PGC-1, coactivating PPAR by 30-fold
as compared with wild-type PGC-1’s 20-fold on a DR-1
luciferase reporter (Fig. 3E). When p160MBP and p67MBP
were coexpressed with PGC-1 or PGC1-3D, PGC1-3D
was resistant to repression by p160MBP and p67MBP. To-
gether, these data indicate that the positive effects of p38
MAPK on PGC-1 activity occur largely via direct
modulation of PGC-1 to diminish p160MBP binding.
It has previously been shown that a titratable repressor
interacts with PGC-1 and is dependent on the leucine
motifs LXXLL (L2), beginning at amino acid 147, and
Figure 2. PGC-1 binds to amino acids 200–400 and to the C terminus of p160MBP. (A) Summary of p160MBP deletion constructs used
in this experiment. (B) GST, labeled G, or GST-PGC1(200–400), labeled P, were incubated with in vitro translated 35S-p160MBP
deletions for 1 h. Interacting proteins were run on an SDS-PAGE gel and visualized by autoradiography.
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Figure 3. p160MBP’s interaction with PGC-1 is modulated by p38 MAPK phosphorylation. (A) GST-PGC1(200–400) was phosphory-
lated in vitro by activated p38 MAPK in the presence of ATP [GST-PGC1(200–400)-P] or mock phosphorylated in the absence of ATP
[GST-PGC1(200–400)]. The GST proteins were then incubated with C2C12 nuclear extracts and interacting proteins were visualized
by Western blot by using antibodies against p160MBP or against cdc16 (Santa Cruz Biotechnology). (B) Flag-tagged PGC-1 (f:PGC1)
was cotransfected with myc-tagged p160MBP (myc-p160MBP) in BOSC cells and after 24 h treated with the cytokines IL-1, IL-1, and
TNF overnight in DMEM + 0.5% BSA. Whole-cell extracts were immunoprecipitated with M2 anti-Flag antibodies (Sigma) and
Western blots were conducted with antibodies against myc or PGC-1 (Santa Cruz Biotechnology). The left panel is a Western blot of
5% of the whole-cell extract before immunoprecipitation and the right panel is a Western blot of the immunoprecipitated proteins.
(C) Gal4-PGC1 was cotransfected in C2C12 cells with a UAS-luciferase reporter and a vector expressing MKK6, the upstream
activator of p38 MAPK. Medium was changed to DMEM + 0.5% BSA after 24 h, and luciferase activity was measured after 48 h.
(Asterisks) P < 0.05, paired t-test. (D) Myc-p160MBP was cotransfected with f:PGC1, f:PGC1 with the phosphorylation sites mutated
to aspartic acid (f:PGC1-3D), or f:PGC1 with selected leucines at L2 and L3 mutated to alanine (f:PGC1-L2/3A). Extracts were
immunoprecipitated with anti-Flag antibodies as described earlier. (E) PGC-1 or PGC1-3D were cotransfected with PPAR, RXR, and
DR-1 luciferase reporter in HIB1B cells. Cells were harvested after 24 h and fold activation over PPAR was graphed. (Asterisks)
P < 0.05, paired t-test. (F) Gal4-PGC1 or Gal4-PGC1-L2/3A were cotransfected with a UAS-TATA-luciferase reporter in C2C12 cells,
and luciferase activity was measured after 24 h. (Asterisks) P < 0.05, paired t-test.
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LLXXL (L3), starting at amino acid 210 (Knutti et al.
2001). Mutation of the leucine motifs to AXXLL and
AAXXL, respectively, relieves the suppressive effects of
the regulatory domain of PGC-1. Figure 3D shows that
a PGC-1 containing mutations in the leucine motifs
(f:PGC1-L2/3A) was unable to coimmunoprecipitate
p160MBP. p160MBP and p67MBP, when transfected into
C2C12 cells, failed to suppress the transcriptional activ-
ity of a version of Gal4-PGC1 containing the leucine
mutations (Gal4-PGC1-L2/3A; Fig. 3F). Because muta-
tion of either the L2 or L3 motif alone was not sufficient
to completely abolish p160MBP repression, we conclude
that both the L2 and L3 motifs contribute to p160MBP’s
interaction with full-length PGC-1 (data not shown).
Despite the fact that the leucine motifs are 50 amino
acids away from the phosphorylation sites, Gal4-PGC1-
L2/3A no longer undergoes phosphorylation-induced in-
creases in transcription (Knutti et al. 2001). This is con-
sistent with the data indicating that p160MBP binding is
regulated by PGC-1 phosphorylation. If p160MBP can-
not bind to the Gal4-PGC1-L2/3A mutant, phosphoryla-
tion of this mutant would not be expected to result in
increased activity via p160MBP dissociation.
Adenoviral expression of p160MBP decreases
PGC-1-mediated respiration and mitochondrial
gene expression
Adenoviral vectors for p160MBP and p67MBP were gener-
ated to investigate their activity on physiological func-
tions of PGC-1. These viruses were used in conjunction
with adenoviral-PGC1 to infect C2C12 muscle cells,
which were then harvested after 48 h for respiration
studies and RNA analyses. As shown in Figure 4, A and
Figure 4. p160MBP suppresses PGC-1’s biological effects in muscle cells. C2C12 myoblasts were coinfected with adenoviral PGC1
and p160MBP. Adenoviral GFP was used in the control infections. After 48 h, (A) total mitochondrial oxygen consumption and (B)
uncoupled respiration were measured in live muscle cells. Uncoupled respiration represents the fraction of mitochondrial respiration
that is not coupled to ATP production and was attained through addition of the ATP-synthase inhibitor oligomycin. (Asterisks)
P < 0.05, repeat ANOVA, a posteriori Tukey test. (C) Same as in A and B, except instead of using cells for oxygen consumption assays,
RNA was harvested and Northern blots were performed. (D) C2C12 myoblasts were coinfected with adenoviral PGC1 and p160MBP
in serum-free media. TNF, IL-1, and IL-1 were added at the time of infection and cells were harvested after 24 h. Real-time PCR
was used to quantitate RNA levels. (Asterisks) P < 0.05, paired t-test; (n.s.) not statistically significant, paired t-test.
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C, and has been shown previously, expression of PGC-1
causes a rise in total mitochondrial oxygen consumption
and the expression of genes of the mitochondrial elec-
tron transport system. Coexpression of p160MBP reversed
the effects of PGC-1, causing a complete elimination of
PGC-1-driven mitochondrial oxygen consumption.
This was accompanied by a reduction in the target genes
cytochrome c and -ATP synthase. There was also a
slight decrease in the respiration of cells infected with
adenoviral GFP and p160MBP, although this did not reach
statistical significance. The small change in basal respi-
ration may be due to the repression of the endogenous
PGC-1 in C2C12 myoblasts, or to an as yet undescribed
activity of p160MBP on respiration. Interestingly, p67MBP
did not alter oxygen consumption or PGC-1 target gene
expression in these experiments despite the data shown
earlier indicating that p67MBP is a more potent repressor
of PGC-1 in transient transfections. Western blots con-
firmed that both adenoviral p160MBP and p67MBP were
expressed efficiently in these experiments, with p67MBP
expressed at slightly higher levels than p160MBP (data not
shown). Thus, it appears that full-length p160MBP protein
is necessary for suppressive function on endogenous PGC-
1 target genes. This suggests that the C terminus of
p160MBP is important for repression on chromatinized, en-
dogenous DNA, but it is not required on plasmid DNA.
We also measured the effect of p160MBP on the un-
coupled fraction of mitochondrial respiration by adding
the drug oligomycin to block ATP synthase. PGC-1 has
been shown to have more potent effects on induction of
mitochondrial leak than on induction of total oxygen
consumption (St-Pierre et al. 2003). Figure 4B shows that
uncoupled respiration is robustly induced by PGC-1,
and p160MBP represses the PGC-1-driven proton leak by
>60%. p160MBP’s repression of proton leak is specific for
PGC-1-infected cells as compared with cells infected
with GFP. Together, these experiments indicate a role
for p160MBP in the suppression of PGC-1’s regulation of
mitochondrial respiration and gene expression.
We next added cytokines and tested whether p160MBP
would still be able to suppress PGC-1 induction of tar-
get genes. Because cytokines lead to phosphorylation of
PGC-1, p160MBP should no longer suppress PGC-1 ac-
tivity. C2C12 myotubes were infected with adenoviral
PGC-1 and p160MBP, with or without cytokines, in the
absence of serum. Because of the toxicity associated with
the cytokines and serum starvation, RNA was harvested
after only 24 h, and subjected to real-time PCR. Al-
though p160MBP suppressed cytochrome c and ATP
synthase expression in the absence of cytokines, addi-
tion of a cocktail of TNF, IL-1, and IL-1 completely
eliminated this suppression (Fig. 4D). This further sup-
ports a model in which p160MBP’s action on PGC-1 is
inhibited by PGC-1 phosphorylation.
p160MBP has intrinsic transcriptional
repressive activity
There are several possible mechanisms, not mutually ex-
clusive, for how p160MBP might mediate repression of
PGC-1 function. Our primary hypotheses were based
on previous work indicating that cytokines altered both
the protein stability and transcriptional activity of PGC-
1. We studied this in two different cell types relevant to
the biology of PGC-1: brown fat and muscle. We first
looked at PGC-1 protein levels in the brown fat HIB1B
cells cotransfected with p160MBP. p160MBP caused a dra-
matic decrease in the amount of full-length PGC-1 pro-
tein (Fig. 5A), and a similar decrease was seen with a
truncated version of PGC-1 containing only the first
400 amino acids. In contrast, a mutant of PGC-1 con-
taining only the first 180 amino acids, which does not
bind to p160MBP, was not affected. The triple aspartic
acid mutant, PGC1-3D, which also does not bind signifi-
cantly to p160MBP, was similarly unchanged. Although
we were unable to ascertain effects of p160MBP on PGC-
1 RNA because of the low transfection, the fact that all
of these versions of PGC-1 are expressed from the same
vector strongly suggests that the differences seen in pro-
tein level represent a change in protein stability rather
than a change in transcript expression from the CMV
promoter.
We also investigated p160MBP-mediated PGC-1 re-
pression in C2C12 muscle cells, the cell type in which
the oxygen consumption assays and target gene studies
were conducted. In contrast to the data shown earlier
with HIB1B, we did not see a clear effect of p160MBP on
PGC-1 protein amount in C2C12 (Fig. 5B). To investi-
gate whether repression occurs through the direct action
of p160MBP on the promoter of PGC-1 target genes, we
used a well-characterized PGC-1 target gene in muscle
cells, myoglobin. PGC-1 coactivates MEF2C on a well-
defined site on the myoglobin promoter (diagram in Fig.
5C; Yan et al. 2001; Handschin et al. 2003).
C2C12myotubes were infected withMEF2C, PGC-1,
and p160MBP. RNA analyses andWestern blots were con-
ducted in parallel to determine the amount of PGC-1
RNA and protein in the presence of p160MBP. Real-time
PCR analysis revealed that p160MBP represses PGC-1-
induced activation of myoglobin by almost 60% without
altering the amount of PGC-1 mRNA or protein (Fig.
5B). We therefore conclude that, in C2C12 myotubes,
p160MBP is working through a mechanism other than
alteration of PGC-1 protein stability.
We next used chromatin immunoprecipitations to ask
whether PGC-1 remained bound to the myoglobin pro-
moter under the influence of p160MBP. C2C12 myotubes
were infected with MEF2C, Flag-tagged PGC-1, and
p160MBP. Protein and DNA were cross-linked and chro-
matin was sheared before immunoprecipitation using
anti-Flag antibodies. PCR with primers flanking the
MEF2C site of the myoglobin promoter was then used to
detect if PGC-1 was bound to the myoglobin promoter.
Figure 5D shows that PGC-1 is recruited to the myo-
globin MEF2C site, but that p160MBP does not alter this
recruitment. Thus, PGC-1 remains bound to the myo-
globin promoter even in the presence of p160MBP’s sup-
pression of this target gene. Western blots for PGC-1
and MEF2C and a PCR of the MEF2C site from input
DNA prior to the immunoprecipitation serve as con-
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Figure 5. p160MBP does not alter PGC-1 protein level or recruitment to DNA. (A) HIB1B brown fat cells were cotransfected with
p160MBP and various versions of PGC-1. Cell extracts were Western blotted for PGC-1. (B) C2C12 myotubes were coinfected with
adenoviral MEF2C, PGC-1, and p160MBP and harvested for RNA and protein. RNA was subjected to real-time PCR analysis to
determine the amounts of PGC-1 and myoglobin transcripts. Protein was blotted with antibodies against PGC-1 or the loading
control actin. (Asterisk) P < 0.05, paired t-test. (C) Diagram of PGC-1 interaction with MEF2C on the myoglobin promoter; sites for
PCR primers for chromatin immunoprecipitation assays are indicated. (D) C2C12 myotubes were coinfected with adenoviral MEF2C,
Flag-tagged PGC-1, and p160MBP. Chromatin immunoprecipitations were carried out using M2 anti-Flag antibodies. The input and
immunoprecipitated DNA were used as templates for PCR with primers flanking the MEF2C site at −130 on the myoglobin promoter.
Primers amplifying a region of the GAPDH gene were used as a negative control. (E) Gal4 fusion protein constructs were transfected
into C2C12 myoblasts with a UAS-tk-luciferase reporter. The cells were harvested after 24 h and luciferase activity was measured. (F)
Similar to E, except 100 µg/mL trichostatin A (TSA) was added after 12 h.
GENES & DEVELOPMENT 285
trols. A region of the GAPDH gene was also used for PCR
from the input and immunoprecipitated DNA, and con-
firmed that PGC-1 specifically immunoprecipitated the
myoglobin promoter, but not GAPDH.
Because p160MBP does not displace PGC-1 from the
promoter of a target gene, we hypothesized that p160MBP
itself might contain inherent transcriptional repressive
activity. Hence, the mere recruitment of p160MBP to
PGC-1 would serve to lower transcription. To study
p160MBP’s intrinsic repressive activity, we fused
p160MBP to Gal4’s DNA binding domain and tested it on
a UAS-tk-luciferase reporter. The tk promoter has sig-
nificant basal transcriptional activity and therefore is
useful for testing transcriptional repressors. We used
Gal4-Groucho, a known transcriptional repressor, as a
positive control for this assay. Gal4-Groucho expression
results in an 80% reduction in transcription. Strikingly,
Gal4-p160MBP and Gal4-p67MBP were capable of repress-
ing the UAS-tk-luciferase reporter to nearly the same
extent as Gal4-Groucho (Fig. 5E). Expression of a version
of p67MBP that was not fused to the Gal4 DNA binding
domain had no effect, confirming that recruitment to the
promoter is essential for this repression. These data are
consistent with a model in which p160MBP binds to
PGC-1 on the DNA and directly represses its transcrip-
tional activity.
A common mechanism of transcriptional repression is
through deacetylation of histones. We used the histone
deacetylase inhibitor trichostatin A (TSA) to investigate
the possibility that p160MBP possesses intrinsic histone
deacetylase activity or recruits a histone deacetylase. In
a transient transfection in C2C12 myoblasts, Gal4-
p160MBP’s repressive activities were diminished by the
addition of TSA (Fig. 5F). This indicates that at least part
of the suppressive activity of p160MBP is dependent on
histone deacetylases. It is notable that TSA had no effect
on Gal-p67MBP, highlighting the functional difference in
the properties of these two molecules. Gal4-HDAC1 was
used as a positive control. These studies provide insight
into the mechanism of p160MBP function, specifically
suggesting the involvement of histone deacetylases.
Discussion
Although most biological regulation at the transcrip-
tional level studied to date is attributed to alterations in
amounts or activities of DNA-binding transcription fac-
tors, it is now clear that major control can be elicited
through regulation of coactivator proteins. The first ex-
ample of this was through the identification of OcaB, a
B-cell selective coactivator of octomer binding proteins
(Luo and Roeder 1995). Perhaps the most dramatic ex-
ample of this, however, has been the coactivator PGC-
1, which is a major regulator of metabolic functions in
many tissues. PGC-1 activates mitochondrial biogen-
esis and respiration in both brown fat and skeletal
muscle, and is induced in the cold in both tissues (Puig-
server et al. 1998; Wu et al. 1999). PGC-1 is also ex-
pressed at high levels in skeletal muscle rich in type I
fibers and can regulate muscle fiber type switching (Lin
et al. 2002). PGC-1 is induced in the liver on fasting,
where it activates mitochondrial -oxidation of fatty ac-
ids and gluconeogenesis (Herzig et al. 2001; Yoon et al.
2001).
Although PGC-1 is greatly regulated at the transcrip-
tional level, one mechanism has been described that in-
dicates that important posttranslational control of this
coactivator also occurs. p38 MAPK directly phosphory-
lates sites in the suppressor domain of PGC-1, and
greatly enhances its transcriptional activity (Puigserver
et al. 2001). Although we originally described this p38
MAPK-mediated modification as a control point in the
well-established role of cytokines in the activation of
energy expenditure in vivo, recent data have shown that
p38 MAPK is also activated downstream of cyclic AMP
signaling in brown fat (Cao et al. 2001). Because cyclic
AMP and CREB have been shown to be major players in
the transcriptional control of PGC-1 expression in
many tissues, this raises the possibility that the p38
MAPK activation of PGC-1 may be part of a coordi-
nated program to increase the function of this coactiva-
tor at several levels simultaneously. Despite the data
pointing to the importance of p38 MAPK modulation of
PGC-1 as a key control point, virtually nothing has
been known about how these phosphorylation sites
might exert their effects.
The data presented here describe p160MBP as a repres-
sor of PGC-1 function. p160MBP has been relatively un-
characterized to date. It was originally cloned as a repres-
sor of c-myb, and its truncated form, p67MBP, was found
to repress c-myb-mediated transcription (Tavner et al.
1998). p160MBP also interacts with the transactivation
domain of the aromatic hydrocarbon receptor. In this
context, p160MBP activates transcription in transient
transfection (Jones et al. 2002). Thus far, the mechanism
of p160MBP-mediated activation or repression has been
unknown.
Several lines of evidence support the notion that
modulation of PGC-1 function by p38 MAPK is medi-
ated, in significant measure, by p160MBP. First, p160MBP
was isolated in an unbiased biochemical purification as
binding to the region of PGC-1, aa 200–400, which is
associated with transcriptional suppression. Second, p38
MAPK-mediated phosphorylation of PGC-1 in vitro
greatly reduces the binding of p160MBP. Third, p160MBP
reduces the transcriptional activity and biological effects
of PGC-1, and in all cases, p38 MAPK-mediated phos-
phorylation reduces or completely blocks all of the ef-
fects of p160MBP. In addition, we have found that the
binding of p160MBP to PGC-1 is reduced by mutation of
leucines at motifs LXXLL (L2), which begins at amino
acid 147, and LLXXL (L3), which begins at amino acid
210. These mutations have been previously suggested by
Kralli and colleagues to block the binding of a putative
titratable repressor of PGC-1 (Knutti et al. 2001).
The discovery of molecular repressors of PGC-1 is
important because all of the experiments conducted
with PGC-1 to date have been gain-of-function experi-
ments. A repressor could provide a valuable tool for
studying the effects of decreasing PGC-1 activity. A
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recent publication has suggested that the docking of the
orphan nuclear receptor estrogen-related receptor 
(ERR) may depress PGC-1 function through the same
negative regulatory domain. However, the docking of
ERR is not modulated by p38 MAPK-mediated phos-
phorylation, a modification known to reverse the func-
tion of the repressor domain (Ichida et al. 2002).
Our earlier work had indicated that the p38 MAPK-
mediated phosphorylation worked to suppress PGC-1
function in at least two distinct ways: via changes in
protein stability and via changes in transcriptional func-
tion that could not be explained simply through the
changes in protein stability (Puigserver et al. 2001). This
was shown most clearly in a mutant of PGC-1 that had
alanine substitutions (3A) at all three of the MAPK phos-
phorylation sites. This protein was stabilized to a com-
parable extent as the fully phosphorylated PGC-1, but
was far less active transcriptionally and biologically than
the phosphorylated protein. The data presented here in-
dicate that p160MBP can dock on PGC-1 and regulate its
transcriptional activity and biological functions, notably
in mitochondrial respiration and expression of genes of
the electron transport system. This suppression seems to
occur without modulation of PGC-1 protein levels, at
least in skeletal muscle, or removal of PGC-1 from
chromatin. As shown in chromatin immunoprecipita-
tion assays (Fig. 5D), PGC-1 remains bound to the myo-
globin promoter at the crucial MEF2 binding site even
under the negative regulation of p160MBP. This suggests
a model whereby p160MBP is recruited to PGC-1 tar-
geted promoters through the suppressor domain of this
coactivator (Fig. 6). That p160MBP has inherent transcrip-
tional suppression activity is shown by the fact that this
molecule can suppress transcription even when cova-
lently linked to the DNA-binding domain of Gal4. Ad-
dition of the histone deacetylase inhibitor trichostatin A
partially reverses this repression, suggesting the involve-
ment of histone deacetylase activity in p160MBP-medi-
ated transcriptional repression.
The role of p160MBP in controlling the stability of
PGC-1 is not completely clear at present. In some cell
types, such as HIB1B, coexpression of p160MBP reduces
the amount of PGC-1 protein, and this reduction is de-
pendent on the p160MBP binding domain of PGC-1. On
the other hand, we have not been able to show an effect
on PGC-1 protein stability in other cell types, such as
C2C12 myotubes. These data suggest that p160MBP can
control the amount of PGC-1 protein, probably via sta-
bility, but that there may be additional molecules in-
volved in this process. The purification of certain sub-
units of the anaphase promoting complex with the
suppressor domain of PGC-1 certainly suggests the pos-
sible involvement of the protein-destruction apparatus
in this process.
The mechanisms illustrated here—namely, the
p160MBP docking on PGC-1 in a p38 MAPK-regulatable
fashion—has therapeutic implications. Particularly in
muscle, PGC-1 has been shown to stimulate glucose
uptake as well as mitochondrial biogenesis and respira-
tion, all associated with increased energy expenditure. In
fact, recent work from two groups has shown a decrease
in expression of PGC-1 and its target genes in the
muscle of type 2 diabetics and prediabetics, individuals
with no disease, but with a high likelihood of developing
diabetes (Mootha et al. 2003; Patti et al. 2003). These
studies have suggested that even a mild to moderate in-
crease in PGC-1 function might benefit these patients.
The data here suggest that inhibition of the docking of
p160MBP on PGC-1 would increase the biological ef-
fects of this coactivator. Although inhibition of protein–
protein interactions by a small molecule might not be
easy, the fact that this docking event is apparently struc-
tured so that it is disrupted by a limited number of phos-
phorylations indicates that the relevant protein surfaces
controlling this binding may not be large. Such an in-
hibitor could prove useful in the treatment of type II
diabetes.
Materials and methods
Preparation of GST fusion proteins and nuclear extracts
Bacterially produced GST-PGC1 fusion proteins were gener-
ated by inducing BL21 cells containing GST-PGC1 plasmids
with 1 mM IPTG for 3 h. The cells were then sonicated and
centrifuged to remove cell debris. The supernatant was incu-
bated with glutathione-sepharose beads to purify the GST pro-
tein. The beads were then washed in PBS and stored at 4°C. To
generate phosphorylated GST-PGC1, we carried out an in vitro
phosphorylation reaction using activated p38 MAPK (Upstate
Biotechnology). Nuclear extracts were prepared from C2C12
myoblasts using the Dignam protocol (Dignam et al. 1983).
Cells were incubated on ice with hypotonic Solution A (10 mM
HEPES-KOH at pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM
DTT, 0.5% NP-40, protease inhibitors) for 5 min, then vortexed
and spun at 1000g for 5 min to pellet the nuclei. The nuclei were
Figure 6. Schematic representation of p160MBP repression of
PGC-1 on DNA; regulation by p38 MAPK signaling events.
p160MBP binds to PGC-1 and represses transcription of PGC-1
target genes. On cytokine or -adrenergic signaling, p38 MAPK
becomes active and phosphorylates PGC-1. The phosphates
disrupt p160MBP binding to PGC-1, leading to increased acti-
vation of PGC-1 target genes.
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resuspended in Solution B (20 mM HEPES-KOH at pH 7.9, 400
mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM EDTA, 15%
glycerol, protease inhibitors) and shaken, not stirred, at 4°C for
20 min to extract nuclear proteins. Samples were spun at
16,000g for 10 min and supernatant was stored at −80°C.
Affinity purification with PGC-1 regulatory domain
C2C12 nuclear extracts were diluted in three volumes of dilu-
tion buffer (20 mM HEPES-KOH at pH 7.9, 1.5 mM MgCl2, 1
mM DTT, 0.2 mM EDTA, 15% glycerol, protease inhibitors)
and precleared on glutathione sepharose beads for 1 h at 4°C.
The extract was then incubated with the GST-PGC1 fusion
proteins overnight at 4°C. After washing in HEGN (20 mM
HEPES at pH 7.6, 0.15 M KCl, 0.1 mM EDTA, 10% glycerol,
0.1% NP-40, 1 mMDTT, protease inhibitors), the GST proteins
were eluted with 20 mM glutathione (20 mM glutathione, 20
mMHEPES at pH 7.6, 0.1 M KCl, 0.1 mM EDTA, 10% glycerol,
0.025% NP-40, 1 mM DTT, protease inhibitors), TCA precipi-
tated, and run on an SDS-PAGE gel. The gels were either sub-
jected to silver staining or Western blotting as indicated.
Protein identification by mass spectrometry
Gel-resolved proteins were digested with trypsin, partially frac-
tionated, and the resulting peptide mixtures analyzed by ma-
trix-assisted laser-desorption/ionization reflectron time-of-
flight (MALDI-reTOF) MS (Reflex III; BRUKER Daltonics), as
described (Erdjument-Bromage et al. 1998); and also using an
electrospray ionization triple quadrupole MS/MS instrument
(API300; ABI/MDS SCIEX) modified with an ultrafine ioniza-
tion source (Geromanos et al. 2000). Selected precursor or frag-
ment ion masses from the MALDI-TOF MS or NanoES-MS/MS
spectra were taken to search a nonredundant protein database,
as described (Winkler et al. 2002). MS/MS spectra also were
inspected for y ion series to compare with the computer-gen-
erated fragment ion series of the predicted tryptic peptides.
GST purifications of 35S in vitro-translated proteins
GST proteins were incubated with 35S-labeled in vitro trans-
lated proteins (TnT kit, Promega) in binding buffer containing
100mMHEPES (pH 7.7), 375mMKCl, 0.5 mM EDTA, 12.5 mM
MgCl2, 0.25% NP-40, and 50% glycerol supplemented with
0.5% milk for 1 h at room temperature. The beads were washed
three times in binding buffer without milk before being resus-
pended in SDS loading buffer and run on SDS-PAGE gels.
Mammalian cell culture and transfections/infections
C2C12, HIB1B, and BOSC cells were grown in Dulbecco’s Modi-
fied Eagle’s Medium supplemented with either 10% cosmic calf
serum or 10% fetal bovine serum. For transcription assays, cells
were transfected with luciferase reporter plasmids as well as
Gal4 fusions or PPAR and p160MBP or p67MBP as indicated.
Trichostatin A (Sigma) was added to cells at 100 µg/mL for 12 h
as indicated. After 1 d, cells were lysed, tested for luciferase
activity, and normalized to -galactosidase activity for transfec-
tion efficiency. To visualize protein, we generated whole-cell
extracts by incubating the cells in lysis buffer (20 mM HEPES-
KOH at pH 7.9, 125 mM NaCl, 0.1% NP-40, 1 mM EDTA, 1
mM DTT, protease inhibitors), freeze-thawing in liquid nitro-
gen, and centrifuging to remove the debris. Immunoprecipita-
tions were carried out in M2 lysis buffer (50 mM Tris-HCl at pH
7.8, 137 mM NaCl, 10 mM NaF, 1 mM EDTA, 1% Triton-X-
100, 0.2% sarkosyl, 1 mM DTT, 10% glycerol, fresh proteinase,
phosphatase inhibitors) for 4 h and washed three times in M2
lysis buffer. For Northern blots, cells were harvested in Trizol
reagent (Invitrogen) for subsequent RNA purification. For cyto-
kine treatment, C2C12 cells were incubated in culture medium
containing 0.5% BSA in place of serum. Human TNF (10 ng/
mL) and human IL-1 and IL-1 (2 ng/mL) were added as indi-
cated for 12 h for coimmunoprecipitations and 24 h for target
gene experiments. For adenoviral experiments, adenoviruses
were generated in 293 cells and infection rates were monitored
using GFP fluorescence.
Oxygen consumption assays
Oxygen consumption measurements were carried out as de-
scribed previously (Wu et al. 1999; St-Pierre et al. 2003). Basi-
cally, cells were isolated by washing with PBS and trypsinizing
for 5 min. DMEM with 10% FBS was added to step the reaction
and the cells were resuspended and spun twice at 1000 rpm for
5 min. Finally, cells were resuspended in DPBS supplemented
with 25 mM glucose, 1 mM pyruvate, and 2% BSA.
Plasmids
p160MBP and its deletion constructs were cloned into the mam-
malian expression vector pcDNA3.1-Myc-His (Invitrogen) be-
tween EcoRV and HindIII. Nuclear localization signals were
added to p160MBP deletions 1–200, 200–400, and 400–580. Gal4-
p160/p67 constructs were cloned into pCMX between EcoRI
and EcoRV. Point mutants were generated using the
Quikchange site-directed mutagenesis kit (Stratagene). Adeno-
p160/p67 constructs were cloned into pAdTrack-CMV between
EcoRV and HindIII before being recombined into pAdEasy.
Chromatin immunoprecipitation assay
C2C12 myotubes were infected with adenoviral MEF2C, Flag-
tagged PGC1, and p160MBP. Cells were harvested after 2 d and
chromatin immunoprecipitation was conducted by using the
Upstate Biotechnology Kit (Cat#17-295) with M2 anti-Flag an-
tibodies. Input DNA and immunoprecipitated DNA were sub-
jected to PCR analysis with the primers 5-AAGTCCAGACA
GTGACCTGGCTG -3 and 5-TGGGTGCCACATGCCCTTC
CTGC-3, which flank the MEF2C site at nucleotide −130 on
the myoglobin promoter (Yan et al. 2001), and the primers 5-
GTCGTGGAGTCTACTGGTGTC-3 and 5-CTAAGCAGTT
GGTGGTGCAGG-3, which flank a region of the GAPDH
gene.
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